{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:28:05Z","timestamp":1769070485754,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca Pharmaceuticals LP"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s13300-020-00815-z","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T07:02:27Z","timestamp":1587193347000},"page":"1467-1480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2\/3 Chronic Kidney Disease"],"prefix":"10.1007","volume":"11","author":[{"given":"Cristian","family":"Guja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Suchower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Marr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. David","family":"Sj\u00f6str\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge A.","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"key":"815_CR1","first-page":"73","volume":"2","author":"H Shahbazian","year":"2013","unstructured":"Shahbazian H, Rezaii I. Diabetic kidney disease; review of the current knowledge. J Renal Inj Prev. 2013;2:73\u201380.","journal-title":"J Renal Inj Prev"},{"key":"815_CR2","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14656566.2019.1571040","volume":"20","author":"SM Heimb\u00fcrger","year":"2019","unstructured":"Heimb\u00fcrger SM, Br\u00f8nden A, Johansen NJ, Dejgaard TF, Vilsb\u00f8ll T, Knop FK. The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. Expert Opin Pharmacother. 2019;20:501\u201310.","journal-title":"Expert Opin Pharmacother"},{"key":"815_CR3","unstructured":"European Medicines Agency. Bydureon. Summary of product characteristics. S\u00f6dert\u00e4lje, Sweden: AstraZeneca AB; 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bydureon-epar-product-information_en.pdf. Accessed 22 Jan 2020."},{"key":"815_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/dom.12084","volume":"15","author":"C Wysham","year":"2013","unstructured":"Wysham C, Grimm M, Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes Metab. 2013;15:871\u201381.","journal-title":"Diabetes Obes Metab"},{"key":"815_CR5","unstructured":"Federal Drug Administration. Bydureon\u00ae BCise\u2122 prescribing information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209210s000lbl.pdf. Accessed 22 Jan 2020."},{"key":"815_CR6","unstructured":"Therapeutic Goods Administration. BYDUREON product information. West Ryde, Australia: Eli Lilly Australia Pty. Limited; 2012. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-exenatide-130205-pi.pdf. Accessed 22 Jan 2020."},{"key":"815_CR7","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2337\/db18-522-P","volume":"67","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, Mentz RJ, Merrill P, et al. Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL). Diabetes. 2018;67:522.","journal-title":"Diabetes"},{"key":"815_CR8","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med"},{"key":"815_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431\u20139.","journal-title":"Lancet"},{"key":"815_CR10","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.2337\/dc12-1333","volume":"36","author":"M Davies","year":"2013","unstructured":"Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care. 2013;36:1368\u201376.","journal-title":"Diabetes Care"},{"key":"815_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","volume":"2","author":"M Diamant","year":"2014","unstructured":"Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2:464\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"815_CR12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28\u00a0week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004\u201316.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"815_CR13","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/dom.12908","volume":"19","author":"KM Gadde","year":"2017","unstructured":"Gadde KM, Vetter ML, Iqbal N, Hardy E, \u00d6hman P, DURATION-NEO-2 study investigators. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: the DURATION-NEO-2 randomized clinical study. Diabetes Obes Metab. 2017;19:979\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"815_CR14","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/dom.13266","volume":"20","author":"C Guja","year":"2018","unstructured":"Guja C, Fr\u00edas JP, Somogyi A, et al. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab. 2018;20:1602\u201314.","journal-title":"Diabetes Obes Metab"},{"key":"815_CR15","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.clinthera.2012.07.007","volume":"34","author":"N Inagaki","year":"2012","unstructured":"Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012;34:1892\u2013908.e1.","journal-title":"Clin Ther"},{"key":"815_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2337\/dc11-1107","volume":"35","author":"D Russell-Jones","year":"2012","unstructured":"Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35:252\u20138.","journal-title":"Diabetes Care"},{"key":"815_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247\u201354.","journal-title":"Ann Intern Med"},{"key":"815_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"815_CR19","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1111\/dom.13303","volume":"20","author":"SV Arnold","year":"2018","unstructured":"Arnold SV, Kosiborod M, Wang J, Fenici P, Gannedahl G, LoCasale RJ. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. Diabetes Obes Metab. 2018;20:2000\u20133.","journal-title":"Diabetes Obes Metab"},{"key":"815_CR20","doi-asserted-by":"publisher","first-page":"e4007","DOI":"10.1097\/MD.0000000000004007","volume":"95","author":"S De Cosmo","year":"2016","unstructured":"De Cosmo S, Viazzi F, Pacilli A, et al. Predictors of chronic kidney disease in type 2 diabetes: a longitudinal study from the AMD Annals initiative. Medicine (Baltimore). 2016;95:e4007.","journal-title":"Medicine (Baltimore)."},{"key":"815_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2125.2007.02890.x","volume":"64","author":"H Linnebjerg","year":"2007","unstructured":"Linnebjerg H, Kothare PA, Park S, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317\u201327.","journal-title":"Br J Clin Pharmacol"},{"key":"815_CR22","first-page":"61","volume":"8","author":"M Davies","year":"2016","unstructured":"Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61\u201381.","journal-title":"Clin Pharmacol."},{"key":"815_CR23","first-page":"241","volume":"8","author":"L MacConell","year":"2015","unstructured":"MacConell L, Gurney K, Malloy J, Zhou M, Kolterman O. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;8:241\u201353.","journal-title":"Diabetes Metab Syndr Obes."},{"key":"815_CR24","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jdiacomp.2017.06.004","volume":"31","author":"ME Trautmann","year":"2017","unstructured":"Trautmann ME, Van Gaal L, Han J, Hardy E. Three-year efficacy and safety of exenatide once weekly: a pooled analysis of three trials. J Diabetes Compl. 2017;31:1415\u201322.","journal-title":"J Diabetes Compl"},{"key":"815_CR25","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s12325-017-0499-6","volume":"34","author":"S Genovese","year":"2017","unstructured":"Genovese S, Mannucci E, Ceriello A. A review of the long-term efficacy, tolerability, and safety of exenatide once weekly for type 2 diabetes. Adv Ther. 2017;34:1791\u2013814.","journal-title":"Adv Ther."},{"key":"815_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2337\/dci16-0032","volume":"39","author":"MJ Davies","year":"2016","unstructured":"Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39:222\u201330.","journal-title":"Diabetes Care"},{"key":"815_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7:515\u201327.","journal-title":"Lancet Diabetes Endocrinol."},{"key":"815_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6:605\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"815_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","volume":"15","author":"D Yabe","year":"2015","unstructured":"Yabe D, Seino Y, Fukushima M, Seino S. \u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15:602.","journal-title":"Curr Diab Rep."}],"updated-by":[{"DOI":"10.1007\/s13300-020-00842-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T00:00:00Z","timestamp":1601769600000}}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00815-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00815-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00815-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T20:26:51Z","timestamp":1618691211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00815-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["815"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00815-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13300-020-00842-w","asserted-by":"object"}]},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"20 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2020","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original article, the Table 1 has published with error.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}